Kimberly-Clark Readies EU Concessions to Clear Path for $40 Billion Kenvue Deal, Sources Say

Kimberly-Clark is preparing to offer concessions, including possible asset sales, to address European antitrust concerns over its $40 billion acquisition of Tylenol maker Kenvue, according to people familiar with the matter. The move comes as the European Commission is expected to formally notify Kimberly-Clark of its concerns this week, the sources said, setting up a critical stretch in the deal's path toward closing.

Concessions Take Shape Ahead of Formal EU Notice

According to reporting by kwsn.com and wmbdradio.com, both citing people familiar with the matter, Kimberly-Clark is readying concessions that could help it win approval for the deal after a preliminary review. The European Commission, which acts as the EU's competition enforcer, is set to formally inform Kimberly-Clark of its concerns this week, the same sources said.

The Commission declined to comment when approached, and Kimberly-Clark and Kenvue did not respond to emailed requests for comment, according to the same reporting. That leaves the specifics of the proposed remedies, including which assets might be sold and in which markets, unconfirmed by the companies themselves.

Feminine Care Emerges as a Flashpoint

While the exact scope of the EU concessions has not been detailed publicly, a recent precedent in another jurisdiction offers a clue to where regulators' attention has focused. Australian authorities cleared the deal last week on condition that Kimberly-Clark divest Kenvue's Carefree and Stayfree period care brands in that country, per the kwsn.com and wmbdradio.com reporting. The same reporting states that the transaction secured conditional approval in South Africa last month, without detailing the conditions attached there.

Interpretation: the Australian remedy points to overlap in feminine care products between the two portfolios as a category that has drawn regulatory scrutiny in at least one jurisdiction. It does not establish what the European Commission's concerns are — the available reporting does not say whether Brussels is focused on the same category or on other parts of the combined portfolio.

The Deal's Scope and Filing Timeline

Kimberly-Clark, the maker of Kleenex tissues and Huggies diapers, announced the acquisition in November of last year. The deal would fold Kenvue's brand portfolio, spanning Tylenol, Listerine mouthwash, and skincare labels Aveeno and Neutrogena, into Kimberly-Clark's existing product range, according to the kwsn.com and wmbdradio.com accounts.

On the regulatory front, Kimberly-Clark formally asked EU regulators to clear the acquisition, a filing reported by Yahoo Finance on August 28, 2026. That filing set in motion the preliminary review process now nearing a decision point, with the Commission expected to lay out its concerns this week, according to the kwsn.com and wmbdradio.com sourcing.

Market Reaction

Shares of both companies moved higher on the news of the prepared concessions. Kimberly-Clark shares rose more than 2.7% in early trading, while Kenvue gained 2.3%, according to kwsn.com's reporting citing market data as of September 14, 2026.

By our calculation, the gap between the two moves was 0.4 percentage points (2.7 minus 2.3), meaning Kimberly-Clark's share gain was roughly 17.4% larger in relative terms than Kenvue's (calculated as (2.7 minus 2.3) divided by 2.3, multiplied by 100). This is a simple arithmetic comparison of the two reported percentage moves on the day and should not be read as a signal of deal certainty or as any kind of forecast; it reflects only the reported reaction in early trading on the news of prepared concessions.

Broader Industry Backdrop

The transaction is unfolding against what kwsn.com and wmbdradio.com described as a challenging consumer goods environment, with shoppers looking for value and companies responding by investing in smaller pack sizes and cutting underperforming units. The reporting did not attribute commentary on that backdrop to either Kimberly-Clark or Kenvue.

What Remains Unconfirmed

Neither Kimberly-Clark nor Kenvue has publicly detailed the substance of the prepared EU concessions, and the companies did not respond to requests for comment cited in the kwsn.com and wmbdradio.com reporting. The European Commission likewise declined to comment. As a result, the precise categories under review in Brussels, the deadline for the Commission's preliminary review, and any timeline for closing the deal are not established in the available reporting.

Bottom Line

Kimberly-Clark appears to be moving proactively to head off EU objections to its Kenvue takeover, with concessions reportedly in preparation ahead of a formal notice of concerns expected this week, according to people familiar with the matter cited by kwsn.com and wmbdradio.com. The Australian divestiture of Carefree and Stayfree offers one concrete signal of where category overlap has already triggered remedies, but the specific EU asks, and how closely they mirror that precedent, remain unconfirmed. Investors reacted positively to the concessions report, though the modest share moves in both stocks reflect an early-stage development rather than a resolved outcome.